Introduction: Frailty syndrome has not been explored in depth in elderly HIV-infected patients. Methods: As of December 2009, a total of 60 patients (out of 160 patients > 60 years) were screened and 20 patients were transferred to our newly created Geriatrics-HIV program. We divided this group of already ''frail patients'' in three different subgroups; the mildly, moderately and the very frail groups based on the number of domains failed during the initial geriatrics screening. Results: The percentages of mildly, moderately, and severely frail elderly patients in our cohort were 20% 50% and 30% respectively. The most common comorbidities found were HTN (60%), and history of AIDS-related opportunistic infections (40%).
Introduction
Elderly populations frequently encounter frailty syndrome, defined as a geriatric syndrome of increased vulnerability to environmental factors. [1] [2] [3] Frailty has been considered synonymous with disability and comorbidity, to be of high prevalence in old age and to confer a high risk for falls, hospitalization, and mortality. 3 Geriatric frailty is found in 20% to 30% of the elderly population over 75 years and increases with advancing age. 4 Many molecular, physiological, and clinical pathways have been hypothesized. 5 Frailty syndrome has not been explored in depth in HIVinfected patients. It appears that HIV-infected population might be more prone to frailty syndrome in view of the aging process and the influence of HIV infection. Recent papers report an increased prevalence of frailty in HIV-infected populations compared to their non-HIV-infected counterparts.
Survival might be shortened in these patients. Factors associated with mortality such as uncontrolled HIV RNA viral load, side effects of antiretroviral therapy, comorbidities, frailty cascade, cognitive dysfunction, and other issues have been connected with early mortality.
The importance of the study of frailty syndrome in HIVinfected patients relies to certain extent on its potential reversibility. This might be in contraposition to what usually happens in non-HIV-infected patients, in whom this problem might be irreversible. The application of preventive measures and the treatment options for frailty syndrome in HIVinfected patients have not been studied in depth.
This article describes the experience of a HIV-Geriatric clinic responsible for the care of elderly frail patients (>60 years of age) after 1 year of follow-up. Factors associated with functional decline of these patients are also described and analyzed.
Prospective trials have studied frailty syndrome and its related factors. Onen et al, 6 in a prospective study, evaluated 445 persons with a mean age of 41.7 years; 71% were male and 63% were African Americans. Those studied had a mean 8.4 years of HIV diagnosis. Frailty prevalence was 9%. Utilizing Fried's frailty scale for evaluation of these patients, the authors concluded that unemployment, greater number of comorbid conditions, past opportunistic illnesses, higher depression severity score, receipt of antidepressants, and lower serum albumin were independent predictors of frailty. 6 Finally, it was found that HIV infection was associated with a premature presentation of frailty.
Desquilbet et al 7 who investigated the relationship between HIV and the prevalence of frailty-related phenotype (FRP) have studied the phenotypic appearance of frailty. The authors defined FRP based on the definition of Linda Fried's frailty index. Subsequently, they assessed the prevalence of frailty among HIV-non-infected individuals followed in the Multicenter AIDS Cohort Study (MACS) between 1994 and 2004 (a total of 1977 individuals contributing 12 155 persons visits). Finally, the authors evaluated the association between FRP and HIV infection before the era of antiretroviral therapy (245 HIV-infected patients contributing to 691 persons visits). They found that HIV infection was strongly associated with FRP prevalence, and that the FRP prevalence for 55-year-old men infected with HIV for <4 years was similar to that of HIV-uninfected men >65 years old.
Desquilbet et al 8 studied the correlation between frailtyrelated phenotype and progressive deterioration of the immune system in HIV-infected man before and after the appearance of highly active antiretroviral therapy in 1046 HIV-infected men from 1994 to 2005. Plasma HIV-RNA viral load and CD4-T count were evaluated as predictors of FRP. The authors found that adjusted prevalence of FRP remained low for CD4-T counts >400. After 1996, CD4-T cell count was the only factor independently associated with FRP. The authors concluded that CD4-T count predicted the development of an FRP among HIV-infected men, independent of antiretroviral therapy use. Finally, the study suggests that the deterioration of the immune system in HIV-infected individuals contributes to the systemic physiologic dysfunction of frailty. These findings might have interesting implications for prevention of frailty syndrome in HIVpopulations.
In a 4-year longitudinal study of the impact of cognitive impairment in the development of frailty syndrome, Avila-Funes et al 9 showed that cognitive impairment improves the predictive validity of the operational definition of frailty due to the fact that it increases the risk of adverse health outcomes in this population (study with 6030 communitydwelling persons aged 65-95). These authors found that cognitive impairment was present in 10%, 12%, and 22% of the nonfrail, prefrail, and frail participants, respectively. Cognitive impairment is an important factor in deterioration of functional status.
Functional decline in frail HIV-infected patients has not been clearly elucidated. Different processes (inflammatory cascades, role of HIV virus, and impact of antiretroviral therapy) may have significant influence on morbidity and mortality of patients. However, the impact of antiretroviral therapy in functional status is still undetermined.
However, in a study of 1008 patients 65 years of age and older, Chang et al 10 studied the outcomes of hospitalized elderly patients with geriatric syndromes. The primary outcome was functional deterioration, and included mortality, rehospitalization, and emergency department visits. The authors found that older age, low mini-mental state examination scores, and low nutrition scores were predictors of functional deterioration. In this study, the average mean age was 63.5, about 50% of patients had certain degree of cognitive impairment, and 55% had nutritional problems Correlates of frailty have been studied in non-HIV patients. Syddall et al 11 investigated social correlates of frailty in a British study of 638 patients (320 men and 318 women). Among the men studied, older age, low level of education, not owning one's home, and reduced car availability proved to be factors associated with increased frailty. It is interesting to note that these surrogates may also apply for HIV-infected populations Predictors of mortality found in a prospective observational study of 401 community-dwelling psychogeriatric patients 12 were older age, male gender, living alone, low body mass index (BMI) <18.5, cardiovascular disease, mobility difficulties, increased number of medicines (>2), and impaired activities of daily living (ADLs). In another study of factors affecting mortality of 376 frail patients with hip fracture, Hershkovitz et al 13 found that dementia and very old age (>84 years of age) were independent predictors of mortality in these patients.
Kumar et al 14 in an evaluation of older patients with cancer found that certain demographic characteristics such as older age, female gender, and African American race are associated with ''Frailty population.'' The authors also found that inadequate functional status; presence of comorbidities; depressive state; social isolation; decline in cognitive dysfunction; poor nutritional status; and polypharmacy, are correlated with frailty and poor outcomes in older patients with cancer. Polypharmacy is a significant risk factor for functional deterioration and poor outcomes in elderly patients and a risk factor for increased morbidity and mortality. 14 Vitamin D deficiency has been associated with frailty syndrome. A study of 444 male and 561 female participants aged 65 years and older from the Inchanti study Shardell et al 15 found that vitamin D insufficiency was associated with frailty only in men. Recent reports mention that patients with HIV frequently present vitamin D deficiency. In a study of 57 HIVinfected-patients in an outpatient clinic, moderate and severe vitamin D deficiency was found in 36.8% and 10.5%, respectively. 16 This deficiency might place HIV-populations at higher risk for falls, fractures, and frail status. The role of vitamin D deficiency as predictor of functional status is yet to be determined.
Methods
From May 2007 to June 2009, 2060 patients with HIV (1361 males, 699 females, 160 >60 years) were evaluated in the HIV Outpatient Program clinic based at the Medical Center of Louisiana in New Orleans. As of December 2009, 60 patients (out of 160 patients) were screened and 20 patients were transferred to our newly created Geriatrics-HIV program. A clinician trained in both Geriatric Medicine and Infectious Diseases, a social worker specializing in geriatric issues, a nurse practitioner, a clinical pharmacist, and a dietitian staff the program.
The patients (10 male and 10 female) were referred to the Geriatrics-HIV program because of identified problems in multiple domains: 10 with cognitive dysfunction, 8 with problems in basic or instrumental activities of daily living (IADLs), 6 with nutritional issues, 5 with depression, 5 with mobility problems, 4 with visual issues, and 2 with hearing difficulties.
These patients were evaluated with a thorough geriatrics assessment and interventions such as vitamin D replacement, intense physical therapy, nutritional assessment, appropriate referrals (ophthalmology, ear nose and throat specialists and so forth), clinical pharmacist evaluation of potential interactions and side effects, and close follow up were undertaken. The Geriatrics HIV team met to discuss potential issues with patients twice per month for the first 3 months and monthly thereafter.
We divided this group of already ''frail patients'' in 3 different subgroups; the mildly frail, the moderately frail, and the very frail group. This distribution correlated with number of domains failed during the initial geriatrics screening (ADLs, IADLs, nutrition, cognitive, hearing and visual screening, depression, and mobility problems). The mildly frail failed only in 1 domain (20%), while the severely frail failed in 3 or more domains and/or died during the first year of follow up (30%), the moderately frail failed in 2 domains of the screening evaluation (50%).
Results
Twenty (20) patients were evaluated and followed (almost 30% of total number of screened patients). There were 12 (60%) male and 8 female (40%), with a mean age of 63.5 years. Seventeen patients were African Americans, two were Caucasians, and one was Hispanic. Two patients died during the follow up. Their average CD4 counts before and after the start of antiretroviral therapy were 186.25 and 384, respectively. Their viral loads before treatment ranged from 1490, 049 copies/mL to 143 copies/ mL. After the start of antiretroviral therapy, their viral loads ranged from 60,873 copies/ mL to none detected.
In relation to comorbidities, the most common found were HTN (60%), AIDS opportunistic infections (40%), chronic obstructive pulmonary disease (COPD; 15%), hepatitis B or C (15%), dementia (15%), cancer (15%), and depression (10%). Approximately 75% of these patients were smokers, 25% used drugs in the past, and 45% used alcohol. With respect to social networks, 75% had positive and well-developed social networks (family and friends close to the patient) and only 20% lived alone.
In terms of laboratory values, we found the following averages results; hemoglobin (Hgb) 12.77, hematocrit (Hct) 37.5, blood urea nitrogen (BUN) 15.15, mean creatinine 1.02, and, interestingly, an average albumin level of 3.65. The mean BMI was 28.02. Testosterone average in males was 262.1 and vitamin D levels had an average of 18.66. Abnormal liver enzymes were found in 5 (25%) patients. Table 1 shows characteristics of frail patients in our cohort.
The average number of medications used per patient was 8.1 with 65% of patients being compliant with their regimens. The most common antiretroviral medications used in this group included NRTIs (90%), NNRTIs (40%), and protease inhibitors (45%). Approximately 10% of patients used other antiretroviral regimens. Three (15%) patients had to change regimens due to noncompliance. Approximately 15% of patients had issues with their medications (renal problems, dizziness, and falls).
All patients underwent a thorough geriatrics assessment after 1 year of follow up and 40% still presented problems with ADLs or IADLs, 55% had nutritional problems (malnutrition), 50% had some form of cognitive dysfunction, 40% continued with depression, and 45% had any form of mobility issues.
In the group of severely frail patients, 16% were female and 64% were male. The mean CD4 counts before and after treatment were 296 and 341, respectively. Their viral load ranged from 385 to 341 039 copies/mL before treatment and not detectable to 3307 copies/mL after start of antiretroviral therapy. Vitamin D level was low (18.5) in all patients and testosterone level was normal (261.75). Other characteristics of the severely frail patients: 50% had hypertension; 20% had dementia; 25% had depression; 100% had other comorbidities; and 33% had an episode of opportunistic infection. In addition, 84% were compliant with their medications, 68% were on a combination of nucleoside reverse transcriptase inhibitor (NRTI)/ nonnucleoside reverse transcriptase inhibitor (NNRTI), 32% on a combination of NRTI/ protease inhibitor (PI), and their average number of medications was 8.7. Lastly, 68% were smokers, 68% used alcohol, 16% did not have any form of social networks, and 32% lived alone. The mildly frail group was composed of 25% males and 75% females. Their mean CD4 count was 117.75 before treatment and 356.5 after treatment. The viral load before treatment ranged from 106 to 687 000 copies/mL and 114 to 60 873 copies/mL after treatment. Vitamin D level was low (19.6) in all patients. A total of 50% had hypertension, 25% had hepatitis, 25% depression, 75% had other comorbidities, 50% had an episode of opportunistic infection, 75% were compliant, and 75% were on a combination of NRTI/PI. In all, 75% were smokers, 25% used alcohol, 25% used drugs, 75% had social networks, and 75% lived alone. Their mean number of medications was 8.3.
The moderately frail group was 60% male and 40% female. Their CD4 count was 180.8 before treatment and 312 after treatment. The viral load ranged from 143 to 640 775 copies/ mL before treatment and from none detected to 8273 copies/ mL after treatment. The mean vitamin D level was low (18.4) and the mean testosterone for males was 262.4. A total of 70% had hypertension, 30% had COPD, 100% had other comorbidities, 70% had a history of AIDS opportunistic infections, 50% were compliant with their medications, 70% were on NRTI/NNRTI combination, 70% were smokers, 50% used alcohol, 30% used drugs in the past, 70% had any form of social networks, and 30% lived alone. The average number of medications was 7.2. Table 2 describes characteristics of mildly, moderately, and severely frail patients in our cohort.
A total of 30% of the patients in this study were frail after an initial geriatrics screening. Eighty-five percent (85%) of the patients in this study were African Americans, which corresponds with the prevalent population in the city and in this clinic.
Hypertension and smoking are factors associated with frail patients in this study. The significance of these variables in the perpetuation of frailty syndrome is unknown.
Discussion
As in the Chang et al study, cognitive impairment and nutritional problems were present in this study and clearly could be indicators of functional deterioration. 10 This is shown in this study as the presence of cognitive dysfunction in 50% of patients and a prevalence of 40% had problems with ADLs or IADLs indicated a higher risk for functional deterioration in our group of patients. In contrast to the findings in Syddall's study noted above, this study did not include social or financial variables as predictors of functional decline. 11 The results of this study correlates with the findings of the study by Kumar et al. 14 The social aspects are interesting to note. It appears that these factors may be protective, as was the case in our study where 75% of patients had well-developed social networks and only 25% of patients lived alone. Further studies in other populations with different characteristics will help to determine whether there are some racial differences in prevalence of frailty.
As has been shown in previous studies, the mean number of medications was higher than that of other studies of elderly patients. The results of this study show an average of 8.1 medications per patient, per se a risk factor to perpetuate frailty status. However, the affects of side effects were few in our study. This is a surprising finding since the interactions and side effects of antiretroviral therapy and other medications used by HIV-infected elderly patients are potentially numerous. The effect of close surveillance performed by a clinician pharmacist, part of the multidisciplinary team, is still to be determined.
In this study, 90% of patients were on antiretroviral treatment and were followed closely by their primary care providers. Approximately 90% of patients were on a NRTIs/ NNRTIs backbone. Whether this may have an impact on functional status is still unknown. Compliance was present in 65% of patients and this may have a significant impact in our results. The response to antiretroviral treatment seems to be appropriate in this group of patients. Our results indicate that the immune response and HIV RNA viral load control are adequate. The impact of different groups of antiretroviral therapy (NRTIs, NNRTIs, PIs, others) on frail HIV-infected patients has not been determined.
As per the results of the Shardell and other studies noted above, low or very low vitamin D levels were present in 100% of our study patients. 15 Lastly, the results of this study showed that 30% of patients were frail after an initial geriatrics screening. This percentage is higher compared to that of community dwellers over the age of 65 (17%-20%). 17 The findings of this study overall is consistent with other studies and is the first study to evaluate the characteristics of frail HIV elderly patients in a Geriatric Assessment Clinic setting. The findings of this study need to be confirmed in future studies involving a larger sample size. Limitations of this study include its retrospective nature, the small number of patients, single institution data, and its short-term follow-up of 1 year. These may be limiting factors and generalizability of results to other populations might not be possible. Frailty syndrome might also be prevalent in other age groups in patients infected with HIV.
Conclusions
Frailty syndrome is a prevalent condition in aging patients and, the prevalence seems to be higher compared to non-HIV-infected patients. The results of this study indicate that immune response and HIV RNA viral load control is adequate in frail HIV patients. However, the impact of different groups of antiretroviral treatment (NRTIs, NNRTIs, and PIs, others) on frail HIV-infected patients had not yet been determined. Social networks appear to be very important in elderly HIV-positive patients. In this study, 75% of our patients had well-developed social networks that might have helped them to overcome depression. It is well know that social isolation has a deleterious effect on HIV-positive patients.
Cognitive impairment, presence of comorbidities, poor functional status, high number of medications used, and past history of any opportunistic infection are factors prevalent in severely frail patients infected with HIV in our cohort. The significance of these factors in development and progression of frailty syndrome in HIV-positive patients needs to be elucidated.
Vitamin D deficiency was confirmed in this study of HIVinfected patients. Whether the lack of vitamin D results in frailty or whether frailty causes vitamin D deficiency has not been determined yet. This deficiency might have contributed to functional decline in these patients. Further studies evaluating the best, if any, preferred regimens of antiretroviral treatment and its impact on survival of frail patients are needed.
More studies are needed to investigate the frailty process in HIV-positive patients, predictor factors of mortality, impact of antiretroviral treatment on survival, and potential reversibility of frailty status in HIV-infected patients.
